Abstracts tagged "chemokines"

Abstract Number: 0999 • ACR Convergence 2020
CXCL13 Is a Key Driver for Migration and Differentiation of Regulatory B Cells
Claire Rempenault¹, Julie Mielle², Kristina Schreiber¹, Pierre Corbeau³, Jacques Morel⁴, Claire Daien⁴ and Rachel Audo², ¹Rheumatology, Montpellier, France, ²Institut de génétique moléculaire de Montpellier (IGMM), Montpellier, France, ³immunology, Nimes, France, ⁴Rheumatology department, CHU Montpellier and University of Montpellier, Montpellier, France
Background/Purpose: Human regulatory B cells still need to be characterized. Given the absence of phenotypical definition, a functional definition based on their ability to secrete…
Abstract Number: 1150 • ACR Convergence 2020
Traditional Laboratory Parameters and New Biomarkers in Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis
Arianna De Matteis¹, Denise Pires Marafon¹, Ivan Caiello¹, Manuela Pardeo¹, Giulia Marucci¹, Emanuela Sacco¹, Giusi Prencipe¹, Fabrizio De Benedetti² and Claudia Bracaglia¹, ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ²Division of Rheumatology, Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy
Background/Purpose: Macrophage Activation Syndrome (MAS) and secondary Hemophagocytic Lymphohistiocytosis (sHLH) are hyperinflammatory conditions caused by a cytokine storm, in which IFNγ plays a pivotal role.…
Abstract Number: 1523 • ACR Convergence 2020
Pulmonary Cytokine, Chemokine and Growth Factor Profiles of Distinct Radiographic Patterns of Interstitial Lung Disease in Systemic Sclerosis
Elizabeth Volkmann¹, Donald Tashkin², Ning Li², Mei Leng², Grace Kim², Jonathan Goldin², Airi Harui² and Michael Roth², ¹University of California, Los Angeles, Los Angeles, CA, ²University of California, Los Angeles, Los Angeles
Background/Purpose: The radiological hallmarks of systemic sclerosis-related interstitial lung disease (SSc-ILD) include interstitial inflammation (ground glass opacity) with reticular changes (fibrosis). The precise pathobiology of…
Abstract Number: 1528 • ACR Convergence 2020
Filgotinib Inhibits Monocyte Differentiation and Pro Inflammatoly Cytokine Production in Osteoblasts
Takeo Isozaki¹, Yuzo Ikari¹ and Tsuyoshi Kasama², ¹Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Koutou-ku Tokyo, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by inflammation and joint destruction. Filgotinib is a selective small molecule inhibitor of JAK 1…
Abstract Number: 1529 • ACR Convergence 2020
Differentially Expressed Chemokines and Cytokines in Peripheral Blood Mononuclear Cells (PBMCs) of Rheumatoid Arthritis (RA) Patients
Noha Elemam¹, Mahmood Hachim², Suad Hannawi³ and Azzam Maghazachi⁴, ¹University of Sharjah, Sharjah, United Arab Emirates, ²Mohammed Bin Rashid University Of Medicine and Health Sciences, Dubai, ³Ministry of Health and Prevention, Dubai, United Arab Emirates, ⁴University of Sharjah, Sharjah
Background/Purpose: Rheumatoid arthritis (RA) is the most prevalent autoimmune disease, where various immune cells are associated such as monocytes, natural killer (NK) cells, B cells,…
Abstract Number: 1531 • ACR Convergence 2020
Characterization of Cytokine/chemokine Profile in Patient-derived M1/ M2 Macrophages to Identify Biomarkers for Genetically-defined Systemic Autoinflammatory Diseases
Farzana Bhuyan¹, Adriana Almeida de Jesus², Kim Johnson³, Jacob Mitchell⁴, Yan Huang⁵ and Raphaela Goldbach-Mansky⁵, ¹NIH, bhetesda, MD, ²Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Bethesda, ³NIH, NIAID, Bethesda, ⁴Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Bethesda, MD, ⁵NIH, Bethesda
Background/Purpose: Genetic mutations in key regulatory molecules of the innate immune system cause autoinflammatory diseases through propagation of hyperinflammatory responses. Monocytes/ macrophages regulate inflammatory processes…
Abstract Number: 1948 • ACR Convergence 2020
Identification of Small Molecules with Efficacy as Steroid Sparing Suppression of Chemokine and Cytokine Production by Rheumatoid Arthritis Fibroblast-like Synoviocytes
Tadashi Hosoya¹, Nikunj Shukla², Yuya Fujita³, Shiyin Yao⁴, Fitzgerald Lao⁴, Hiroyuki Baba¹, Shinsuke Yasuda⁵, Howard Cottam⁴, Dennis Carson⁴, Tomoko Hayashi⁴ and Mary Corr⁶, ¹Department of Rheumatology, Tokyo Medical and Dental University (TMDU), Tokyo, Tokyo, Japan, ²Moores Cancer Center, University of California San Diego, San Diego, CA, ³Department of Medicine, University of California San Diego, San Diego, CA, ⁴Moores Cancer Center, University of California San Diego, San Diego, ⁵Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Tokyo, Japan, ⁶Department of Medicine, University of California San Diego, San Diego
Background/Purpose: Target-based drug discovery has expanded our therapeutic armamentarium in the treatment of inflammatory and autoimmune diseases. Despite these advances, glucocorticoids (GC) remain reliable agents…
Abstract Number: 1952 • ACR Convergence 2020
Activated Memory T Cells Produce Ligands That Cause NF-κB-dependent Inflammatory Activation of the Endothelium: Identification of Novel Therapeutic Targets
Kim Jeucken¹, Jan Piet van Hamburg¹, Lotte Kocken¹ and Sander Tas², ¹Amsterdam Rheumatology and Immunology Center (ARC), Department of Rheumatology and Clinical Immunology, Department of Experimental Immunology and Amsterdam Infection and Immunity Institute, Amsterdam UMC; location AMC, University of Amsterdam, Netherlands, Amsterdam, Netherlands, ²Amsterdam Rheumatology and Immunology Center (ARC), Department of Rheumatology and Clinical Immunology, Department of Experimental Immunology and Amsterdam Infection and Immunity Institute, Amsterdam UMC; location AMC, University of Amsterdam, Netherlands, Utrecht, Netherlands
Background/Purpose: Endothelial cells (EC) are important contributors to inflammation via expression of inflammatory mediators, including cytokines, chemokines and adhesion molecules. Production of these inflammatory mediators…
Abstract Number: 0285 • ACR Convergence 2020
CXCL13 Neutralization Reduces Neuropsychiatric Manifestations in MRL/lpr Mice
Michelle Huang¹, Ariel Stock¹ and Chaim Putterman¹, ¹Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Targeted treatments for neuropsychiatric systemic lupus erythematosus (NPSLE) remain challenging to develop due to the unclear pathogenesis of the disease. Our laboratory has previously…
Abstract Number: 0386 • ACR Convergence 2020
Phase 1 Clinical Study of MGTA-145 in Combination with Plerixafor Shows Rapid Single-Day Mobilization and Collection of CD34+ Hematopoietic Stem Cells Without G-CSF
John DiPersio¹, Jonathan Hoggatt², Steven Devine³, David Scadden², Haley Howell⁴, Veit Schmelmer⁴, Glen Raffel⁴, Pat Falahee⁴, Kevin Goncalves⁴, William Savage⁴ and John Davis⁴, ¹Washington University, Saint Louis, ²Massachusetts General Hospital, Boston, ³National Marrow Donor Program, Minneapolis, ⁴Magenta Therapeutics, Cambridge
Background/Purpose: Autologous hematopoietic stem cell (HSC) transplantation is a recommended therapeutic option for selected patients with scleroderma and other autoimmune diseases. HSC transplant requires collection…
Abstract Number: 079 • 2020 Pediatric Rheumatology Symposium
Traditional Laboratory Parameters and New Biomarkers in Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis
Arianna De Matteis ¹, Denise Pires Marafon ², Ivan Caiello ², Manuela Pardeo ², Giulia Marucci ², Emanuela Sacco ², Giusi Prencipe ², Fabrizio De Benedetti ² and Claudia Bracaglia², ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Lazio, Italy, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy
Background/Purpose: Macrophage Activation Syndrome (MAS) and Secondary Hemophagocytic Lymphohistiocytosis (sHLH) are hyperinflammatory conditions caused by a cytokine storm. Prompt recognition and early treatment are essential…
Abstract Number: 9 • 2019 ACR/ARP Annual Meeting
Chemokine CXCL 10 Gene Expression as a Potential Activity Biomarker of Systemic Lupus Erythematosus
Julian Torres Vazquez¹, Alejandro Corzo Cruz ², David Alberto Comoto Santacruz ² and Omar Eloy Muñoz Monroy ¹, ¹Universidad del Ejército y Fuerza Aérea/ Esc. Mil. Gdos. Snd., SEDENA, Mexico City, Distrito Federal, Mexico, ²Universidad del Ejército y Fuerza Aérea/ Esc. Mil. Gdos. Snd., SEDENA, Mexico City, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by a wide range of systemic dysfunctions as well as an elevated erythrocyte sedimentation rate. Chemokine CXCL 10…
Abstract Number: 17 • 2019 ACR/ARP Annual Meeting
Transcription Factor Fli-1 Impacts Lupus Nephritis by Orchestrating CXCL10/CXCR3 Axis
Xuan Wang¹, Mara Lennard Richard ¹, Tomika Caldwell ², Brittany Henry ², Tammy Nowling ², Jim Oates ³, Gary Gilkeson ⁴ and Xian Zhang ¹, ¹Medical University of South Carolina, Charleston, SC, ²Medical University of South Carolina, Charleston, ³Division of Rheumatology & Immunology/Medical University of South Carolina, Charleston, SC, ⁴Division of Rheumatology & Immunology/Ralph H. Johnson VA Medical Center/Medical University of South Carolina, Charleston, SC
Background/Purpose: Lupus nephritis is a major cause of death in both animal models and human patients. Expression of Fli-1, a member of the Ets family…
Abstract Number: 21 • 2019 ACR/ARP Annual Meeting
Immuno-Phenotypic Analysis of Peripheral Blood Mononuclear Cells in Rheumatoid Arthritis Patients Treated with E6011, a Humanized Anti-Fractalkine Monoclonal Antibody
Tomohiro Yamada¹, Jungo Kakuta ¹, Eri Fusaoka-Nishioka ¹, Jun-ichi Ito ², Nobuyuki Yasuda ³, Tetsu Kawano ³ and Toshio Imai ³, ¹KAN Research Institute Inc., Kobe, Japan, ²EISAI Co. Ltd., Tsukuba, Japan, ³KAN Research Institute, Inc., Kobe, Japan
Background/Purpose: Fractalkine (FKN) and its solo receptor CX3CR1 are deeply involved in the pathogenesis of rheumatoid arthritis (RA). FKN is expressed on vascular endothelium, while…
Abstract Number: 532 • 2019 ACR/ARP Annual Meeting
A Phase 2 Study of E6011, an Anti-Fractalkine Monoclonal Antibody, ㏌ Patients with Rheumatoid Arthritis Inadequately Responding to Biologics
Yoshiya Tanaka¹, Tsutomu Takeuchi ², Hisashi Yamanaka ³, Toshihiro Nanki ⁴, Hisanori Umehara ⁵, Nobuyuki Yasuda ⁶, Fumitoshi Tago ⁷, Yasumi Kitahara ⁸, Makoto Kawakubo ⁷, Hayato Hisaki ⁸, Seiichiro Hojo ⁸, Tetsu Kawano ⁶ and Toshio Imai ⁶, ¹University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ²Keio University School of Medicine, Tokyo, Japan, ³Sanno Medical Center, Minato-ku, Tokyo, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan, ⁵Nagahama City Hospital / Division of Rheumatology and Immunology, Nagahama, Japan, ⁶KAN Research Institute, Inc., Kobe, Japan, ⁷Eisai Co., Ltd., Tokyo, Japan, ⁸Eisai Co., Ltd., Bunkyo-ku, Japan
Background/Purpose: Fractalkine (CX3CL1, designated as FKN hereafter) is the sole member of the CX3C-chemokine which leads to dual actions, chemotaxis and cell adhesion for leukocytes…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].